Good
Partially Aligned
Patient Risk:
Low
Summary
Most mechanistic and drug-structure claims align with the provided label excerpts (Sections 11 and 12.1). Several classification/positioning claims (biologic classification, biosimilar dependence, “approved biologic product” wording) are not supported by the provided label text, and the review does not cover safety-critical label sections.
Category Scores
Accurate Statements
Ultomiris is a monoclonal antibody.
11 DESCRIPTION (ravulizumab-cwvz is a humanized monoclonal antibody (mAb)).
Ultomiris is a lab-made protein designed to bind to a specific target in the body.
11 DESCRIPTION (produced in CHO cells) and 12.1 Mechanism of Action (specifically binds complement protein C5 with high affinity).
Ultomiris works by binding to specific proteins in the immune complement pathway.
12.1 Mechanism of Action (specifically binds complement protein C5; inhibits cleavage to C5a and C5b; prevents MAC formation).
Unsupported Statements
Drugs that are monoclonal antibodies like ravulizumab are classified as biologics.
The provided label excerpts identify it as a monoclonal antibody but do not state a general classification rule as “biologics.”
Whether a specific version of Ultomiris counts as a biosimilar depends on the manufacturer and approval status of that product.
No biosimilar/manufacturer/approval-status guidance is present in the provided label excerpts.
Contradictions
Important Omissions
The claim set includes multiple safety-relevant label components (e.g., contraindications/boxed warnings/dosing/administration/specific populations), but no such content was evaluated because the provided excerpts do not include those sections. This limits assessment of overall on-label accuracy for safety-critical statements.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
No safety-critical dosing/contraindication/monitoring statements were made in the extracted claims; however, the audit is limited because safety-critical label sections were not provided in the reviewed text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several non-mechanistic classification/wording claims are not supported by the provided label excerpts (biologic classification, biosimilar dependence, and explicit “approved biologic product” linkage).
Suggested Improvement
Restrict statements to what is explicitly supported in the provided label text (e.g., describe it as a humanized monoclonal antibody that specifically binds C5) and avoid assertions about “biologic”/“approved biologic product” terminology or biosimilar dependence unless supported by the label.